Cardiomyopathy and heart failure in diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 4, 2001, Pages 1031-1046

  Tang, W H Wilson ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE SEVERITY; HEART FAILURE; HUMAN; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0035170135     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70226-7     Document Type: Article

References (99)

1. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
2. Preclinical abnormality of left ventricular function in diabetes mellitus
3. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: Results from the DIGAMI study
4. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly
5. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus
6. Diabetes as a risk factor for sudden death
7. A post-mortem study of vascular disease in diabetics
8. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure
9. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemia or monischemic dilated cardiomyopathy
10. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
11. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
12. The clinical implications of diabetic heart disease
13. Diabetes predicts congestive heart failure risk in the elderly
14. Val-HeFT (Valsartan Heart Failure Trial)
15. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
16. National trends in the initial hospitalization for heart failure
17. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
18. Safety and efficacy of treatment with metoprolol CR/XL in diabetic patients with heart failure
19. Non-invasive evaluation of left ventricular performance in 294 diabetic patients without clinical heart disease
20. The pathophysiology of myocardial ischaemia
21. Impact of diabetes on cardiac structure and function. The Strong Heart Study
22. Diabetes aggravates heart failure progression in ischemic but non-ischemic heart failure
23. Metformin: A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus
24. Myocardial alterations in diabetes and hypertension
25. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus
26. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study)
27. Ramipril prevents cardiovascular events in high risk diabetic participants: Results from the HOPE study
28. Significant weight gain with rezulin therapy
29. Outcome of patients with diabetes mellitus and myocardial infarction treated with thrombolytic agents
30. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study
31. Diabetes and decline in heart disease mortality in U.S. Adults
32. Detrimental influence of female gender in patients with congestive heart failure and diabetes mellitus
33. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
34. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
35. Effect of beta-blocker therapy on insulin resistance in patients with dilated cardiomyopathy: The use of homeostasis model assessment (HOMA), insulin resistance index
36. The myocardial and vascular pathology of diabetic cardiomyopathy
37. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO-HOPE Substudy
38. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients
39. Pulmonary edema associated with troglitazone therapy
40. Troglitazone-induced pulmonary edema
41. Glycemic control and heart failure among adult patients with diabetes
42. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The Carvedilol-Metoprolol Study
43. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy
44. Role of diabetes in congestive heart failure: The Framingham Study
45. Diabetes and cardiovascular disease: The Framingham Study
46. Mortality among diabetics in a national health sample
47. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study
48. Asthma and diabetes mellitus
49. Diabetic angiopathy: A specific vascular disease
50. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction
51. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study
52. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): Effects on mortality at 1 year
53. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction
54. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study
55. The natural history of diabetes-related complications: The UKPDS experience. United Kingdom Prospective Diabetes Study
56. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: Findings from the GUSTO-IIb Study
57. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results
58. The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: A 15-year follow-up study
59. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
60. Impact of diabetes on mortality after the first myocardial infarction
61. Clinically unrecognized dysfunction in young diabetic patients
62. Left ventricular systolic dysfunction in middle-aged patients with diabetes mellitus
63. Admission plasma glucose: Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients
64. Does diabetes affect LV structure and systolic function independent of blood pressure, age and gender? A population sample-based study from the Hypertension Genetic Epidemiology Network (HyperGEN) Study
65. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral an/ or aortic valve disease
66. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of the disease
67. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota
68. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II
69. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy
70. Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus
71. Ten-year trends in hospital care for congestive heart failure: Improved outcomes and increased use of resources
72. The UGDP controversy: Clinical trials versus clinical impressions
73. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure
74. Evidence of cardiomyopathy in familial diabetes mellitus
75. Treatment of patients admitted to hospital with congestive heart failure: Speciality-related discrepancies in practice patterns and outcomes
76. Atherosclerosis in persons with hypertension and diabetes
77. New types of cardiomyopathy associated with diabetic glomerulosclerosis
78. Non-invasive estimation of myocardial performance in patients with diabetes: Effect of alcohol administration
79. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: Results from the ATLAS trial
80. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity and cardiovascular morbidity
81. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus
82. Echocardiographic features of impaired ventricular function in diabetes mellitus
83. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry
84. Insulin resistance in patients with idiopathic dilated cardiomyopathy assessed by fluorodeoxyglucose positron emission tomography imaging: Implications for metabolic intervention?
85. Left ventricular remodeling does not explain the increased incidence of congestive heart failure in diabetics: The SAVE experience
86. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis
87. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure
88. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure
89. Insulin resistance in chronic heart failure
90. Insulin resistance is associated with the reversal of left ventricular remodeling following carvedilol
91. Pulmonary edema associated with rosiglitazone and troglitazone
92. Diabetic heart disease: Clinical considerations
93. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 30
94. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
95. A comparison of the pathologic spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease
96. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
97. Angiographic findings and outcomes in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-1 experience
98. Reduced myocardial flow reserve in noninsulin-dependent diabetes mellitus